XNAS
ICCM
Market cap2mUSD
Oct 08, Last price
1.13USD
1D
-1.74%
1Q
-69.04%
IPO
-64.93%
Name
Icecure Medical Ltd
Chart & performance
P/E
—
P/S
0.75
EPS
—
Div yield, %
—
Shrs. gr., 5y
29.99%
Rev. gr., 5y
-3.72%
Revenues
3m
+2.67%
Net income
-15m
L-1.70%
CFO
-15m
L+16.01%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Key people
Chairman of the Board · since 2017
Eyal Shamir
Chief Executive Officer, Director · since 2017
Ronen Tsimerman
Vice President - Finance, Vice President - Operations · since 2018
Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance · since 2007
Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing · since 2019
External Director · since 2011
External Director · since 2019
Oded Tamir
External Director · since 2013
Independent Director · since 2012
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||